A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria =2 years of Age - PTC923-PKU-301

开始日期2024-05-14

申办/合作机构

PTC Therapeutics, Inc.

NCT06302348

/ Recruiting临床3期

A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin

The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.

开始日期2024-03-04

申办/合作机构

PTC Therapeutics, Inc.

NCT05166161

/ Recruiting临床3期

A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria

The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.

开始日期2022-02-14

申办/合作机构

PTC Therapeutics, Inc.

100 项与墨蝶蛉相关的临床结果

登录后查看更多信息

100 项与墨蝶蛉相关的转化医学

登录后查看更多信息

100 项与墨蝶蛉相关的专利（医药）

登录后查看更多信息

466

项与墨蝶蛉相关的文献（医药）

2025-08-01·FOOD CHEMISTRY

A comprehensive analysis of meat quality degradation and identification of spoilage markers in chicken during refrigerated storage using multi-method approach

Article

作者: Liu, Yifan ; Zhang, Ming ; Shu, Jingting ; Tu, Yunjie ; Shan, Yanju ; Ju, Xiaojun ; Ji, Gaige

In order to better understand the stability and safety of chicken meat during its storage, to comprehend the changing law of chicken meat, and to screen markers that could characterize the deterioration of chicken meat. In this study, traditional methods for the determination of physicochemical indicators, gas chromatography-ion mobility spectrometry (GC-IMS), electronic nose, and electronic tongue were used to elucidate the quality profiles of chilled chickens during the shelf-life of 0, 1, 2, 4, 6, 8, and 10 d at 4 °C, and non-targeted and targeted metabolomics were utilized for the screening and validation of deterioration markers of chicken meat. The results indicated that the texture of the chilled chicken changed first, followed by volatile flavors. Important aldehydes degrade and ketones and alcohols increase in chicken during storage. Purine metabolism was identified as the primary pathway influencing the deterioration of meat quality, with IMP and AICAR emerging as potential markers for meat quality deterioration. This study systematically analyzed the change rule of chicken meat during its shelf-life, screened markers that could characterize the deterioration of chicken meat, and these results provided a scientific basis for the quality control and shelf-life prediction of chicken meat. Additionally, it laid a foundation for the development of more effective preservation technology, deterioration early warning systems, and fast and convenient detection methods.

2025-07-01·PLANT AND SOIL

Microbial inoculant-induced modifications of rhizospheric metabolites and microbial communities enhance plant growth

作者: Yang, Xinxin ; Zhang, Jinchi ; Sun, Lianhao ; Liu, Xin ; Tang, Yingzhou ; Li, Chong ; Nie, Hui ; Shi, Yuxuan ; Liu, Manda ; Xu, Xian ; Zeng, Jingyi ; Zhou, Yuexiang

Microbial inoculants play important roles in the remediation of abandoned mine sites by stimulating plant growth.However, further investigations are required to elucidate their impacts on soil microbial communities and metabolites in this process.For this study, we employed amplicon sequencing and Liquid Chromatog.-Tandem Mass Spectrometry (LC-MS/MS) techniques to examine the responses of soil microbial communities and metabolic functions to microbial inoculants using a pot experimentOur findings indicated that microbial inoculants significantly influenced the structures of both bacterial and fungal communities.Network analyses revealed that microbial inoculants enhanced the stability and complexity of bacterial co-occurrence networks while reducing those of their fungal counterparts.Moreover, microbial inoculants increased the importance of stochastic processes in community assembly, particularly within fungal communities.Metabolomic analyses showed that microbial inoculants significantly modified the metabolic profiles of rhizospheric soil and upregulated metabolic pathways of phenylpropanoids and isoflavonoids.Correlation analyses and structural equation modeling (SEM) anal. further showed that microbial inoculants promote plant growth by influencing keystone microbial genera and the metabolism of phenylpropanoids and isoflavonoids.Overall, this study demonstrated that microbial inoculants promote plant growth through the modification of rhizospheric keystone microbial taxa and the metabolism of phenylpropanoids and isoflavonoids.These results offer valuable insights into the complex biol. processes influenced by microbial inoculants in the rhizosphere.

2025-05-24·EXPERT OPINION ON PHARMACOTHERAPY

Sepiapterin for the treatment of phenylketonuria

Review

作者: Hooper, Amanda J. ; Bell, Damon A. ; Burnett, John R. ; Williams, Robin A.

INTRODUCTION:

Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Untreated, PKU may result in severe and irreversible intellectual impairment due to marked hyperphenylalaninemia (HPA). Guidelines recommend lifelong reduction in Phe levels, usually achieved via a strict low-protein diet and sometimes medications.

AREAS COVERED:

We discuss the role of tetrahydrobiopterin (BH₄), an essential PAH cofactor in Phe metabolism, describe the pharmacodynamics, pharmacokinetics, and metabolism of sepiapterin, as well as reporting on its efficacy and safety in children and adults with PKU.

EXPERT OPINION:

Sepiapterin, an oral synthetic form of a natural precursor of BH₄, can reduce HPA in some patients with PKU. In relatively short-term studies, sepiapterin has been shown to be safe, well tolerated, and like the BH₄ analog sapropterin dihydrochloride effective in reducing blood Phe levels in responsive individuals. The reductions in blood Phe observed with sepiapterin in the phase III APHENITY trial has the potential to allow more PKU patients to attain Phe treatment targets or alternatively easing of the onerous dietary Phe restrictions. Results of longer-term studies in patients with PKU, including neurocognitive and functional outcomes, nutritional status, and quality of life are awaited.

项与墨蝶蛉相关的新闻（医药）

2025-09-02

·PRNewswire

RareMed Announces Expansion of Relationship with PTC Therapeutics

PITTSBURGH, Sept. 2, 2025 /PRNewswire/ -- RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience™. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of those living with PKU by offering an innovative treatment option that addresses their unique needs. Support for Patients and Providers RareMed will be providing non-commercial pharmacy dispensing services to support patients in challenging circumstances. These services are designed to provide both patients and healthcare providers with appropriate assistance. To provide seamless access and support, RareMed RareSupport® Team is expanding. A larger team of liaisons will play a crucial role in providing outreach and coordination efforts across PTC's supported therapies so that every patient may receive appropriate, personalized care and attention, while leadership will provide guidance, oversight, and compliance support. Commitment to Care RareMed's commitment to providing care extends beyond just the launch of new therapies. The program's support framework is designed to assist patients and providers alike in navigating the treatment landscape with confidence. By expanding the team, RareMed aims to facilitate a smoother, more coordinated experience for all stakeholders involved in the treatment process. As RareMed continues to grow and adapt to the evolving needs of its patients, the company's focus remains steadfast on delivering compassionate, effective, and timely care. About Phenylketonuria Phenylketonuria (PKU) is a rare, inherited metabolic disease, which affects the brain. It is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe). If left untreated or poorly managed, Phe—an essential amino acid found in all proteins and most foods—can build up to harmful levels in the body. This causes severe and irreversible disabilities, such as permanent intellectual disability, seizures, delayed development, memory loss, and behavioral and emotional problems. Newborns with PKU initially do not have any symptoms, but symptoms are usually progressive, and damage caused by toxic levels of Phe in the first few years of life is irreversible. Diagnosis of PKU usually takes place during newborn screening programs. There are an estimated 58,000 people living with PKU globally. About RareMed RareMed Solutions is the nation's only concierge patient services provider, delivering award-winning care to patients living with complex conditions. RareMed partners with biopharma to transform the lives of patients afflicted with devastating complex conditions by accelerating access to biomedical breakthroughs. RareMed offers case management, co-pay, coupon and financial assistance programs, reimbursement support, nursing support, healthcare professional education, patient adherence & education, and non-commercial pharmacy dispensing services to all fifty states from its headquarters in Pittsburgh, Pennsylvania and bases across the country. RareMed's advanced AI-integrated hub technology offerings, including the revolutionary RarePath® platform, provide unparalleled management and analytics capabilities to biopharma across the nation. The company has a breadth of experience developing, transitioning, and maintaining therapy-specific solutions that ensure unparalleled manufacturer & patient satisfaction across a variety of patient services models. RareMed's undivided complex disease focus, high caliber associates, fully dedicated teams, and sophisticated proprietary technology enable it to address the unique needs of complex disease patients. RareMed has been consistently recognized as a top workplace in the nation by USA Today and Newsweek and continually raises the benchmark for patient experience according to MMIT patient satisfaction surveys, in which the team recently achieved a perfect 100-point net promoter score. Visit RareMed's website at . SOURCE RareMed Solutions WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-08-14

·PMLiVE

FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

The US Food and Drug Administration (FDA) has approved PTC Therapeutics’ Sephience (sepiapterin) to treat the rare metabolic disorder phenylketonuria (PKU). The drug has been authorised in combination with a phenylalanine-restricted diet to treat hyperphenylalaninemia (HPA) in adult and paediatric patients aged one month and older with sepiapterin-responsive PKU. Affecting one in every 13,500 to 19,000 newborns in the US, PKU is a genetic disorder caused by a deficiency in the enzyme needed to metabolise phenylalanine, an amino acid present in virtually all protein-containing foods. As a result, phenylalanine builds up in the blood and, if left untreated, causes progressive and severe neurological impairment. Sephience, which was recently approved by the European Commission, is a natural precursor of the enzymatic co-factor BH4 and designed to effectively reduce blood phenylalanine levels. The FDA’s decision on the drug was based on results from the late-stage APHENITY trial, in which the mean percent phenylalanine reduction in sepiapterin-treated patients was 63%, rising to 69% in a subset of classical PKU patients. Also supporting the approval was data from the APHENITY long-term extension (LTE) study, in which more than 97% of patients participating in the phenylalanine tolerance protocol demonstrated the ability to liberalise their diet while on sepiapterin treatment, with a mean increase in protein intake of 126%. Commenting on the latest approval of the drug, PTC’s chief executive officer, Matthew Klein, said: “We are excited to have reached this important milestone for those affected by PKU. The broad labelling reflects the potential of Sephience to meet the significant unmet need of PKU patients.” Klein added that the company’s customer-facing teams are ready to bring the therapy to eligible patients in the US “as quickly as possible”. Also welcoming the authorisation, Catherine Warren, executive director of the National PKU Alliance, said: “This progress brings renewed hope, and we are eager to see the positive impact this new treatment option will have on advancing care and potentially improving quality of life for individuals of all ages and PKU subtypes that respond to this therapy.”

上市批准临床结果

2025-08-12

·药事纵横

2025年7月FDA新药获批速览

本文简单盘点了2025年7月份FDA新药审批情况，看看有哪些药界新星闪亮登场，给生命健康带来了新希望：【SEPHIENCE】公司：PTC Therapeutics 批准日期：2025年7月28日治疗：苯丙酮尿症（PKU）近日，PTC Therapeutics宣布，FDA已批准Sephience（sepiapterin）用于治疗儿童和成人苯丙酮尿症（PKU）患者。此次批准适应症范围广泛，适用于1个月及以上、对sepiapterin有应答的成人和儿童高苯丙氨酸血症（HPA）患者。此次FDA批准主要基于3期APHENITY临床试验中显著的疗效与安全性数据，并在APHENITY长期延伸研究中验证了治疗效果的持续性。其中APHENITY试验的结果已发表在著名医学期刊《柳叶刀》上。分析显示，接受sepiapterin治疗的患者平均苯丙氨酸减少63%。超过80%的患者血液苯丙氨酸水平降低到美国和欧盟对PKU儿童和成人患者苯丙氨酸水平的目标指标以下。【ANZUPGO】公司：LEO Pharma 批准日期：2025年 7月23日治疗：中重度慢性手部湿疹（CHE） LEO Pharma近日宣布，FDA已批准Anzupgo（delgocitinib）乳膏（20 mg/g），用于局部治疗对外用糖皮质激素应答不佳或不适合使用糖皮质激素的中重度慢性手部湿疹（CHE）成人患者。根据新闻稿，Anzupgo乳膏是专门用于治疗中重度慢性手部湿疹成年患者的首个获FDA批准的疗法。Anzupgo是一款“first-in-class”的外用泛JAK抑制剂，可抑制造成慢性炎症皮肤疾病病变的JAK-STAT信息通路的活化。之前公布的DELTA 1和DELTA 2两项临床3期试验，评估了Anzupgo相较于安慰剂用于治疗CHE的安全性和疗效。治疗成功定义为研究者整体评估的慢性手部湿疹治疗成功（IGA-CHE TS）评分为0（皮损清除）或1（皮损几乎清除），且较基线至少提高两级。试验数据显示，在第16周时，Anzupgo治疗组与载体对照组相比，有更大比例的患者达到IGA-CHE治疗成功的标准。DELTA 1中Anzupgo治疗组达到治疗成功标准的患者比例为20%，对照组为10%。在DELTA 2中Anzupgo治疗组达标的患者比例为29%，对照组为7%（两项试验均p≤0.0055）。【Ekterly】公司：KalVista Pharmaceuticals 批准日期：2025年7月3日治疗：遗传性血管性水肿 KalVista制药公司于7月7日宣布，FDA已批准Ekterly(sebetralstat，300mg)片剂，用于治疗成人和12岁及以上儿童患者的遗传性血管性水肿(HAE)急性发作。Sebetralstat是一种口服血浆激肽释放酶抑制剂，靶向激肽释放酶-激肽系统级联。通过抑制高分子量激肽原的裂解，该药可减少缓激肽的产生，从而缓解HAE的症状。值得注意的是，Ekterly是美国FDA批准的首个也是唯一一个用于治疗12岁及以上人群遗传性血管性水肿急性发作的口服按需疗法。此项批准基于随机、三方交叉、3期KONFIDENT试验(ClinicalTrials.gov标识符：NCT05259917)的数据，该试验评估了Sebetralstat在12岁及以上患有1型或2型遗传性血管性水肿(HAE)的儿童和成人中的疗效和安全性。研究参与者被随机分配接受Sebetralstat 300mg、Sebetralstat 600mg或安慰剂治疗。研究结果显示，与安慰剂相比，Sebetralstat 600mg组患者的HAE发作症状缓解速度显著加快。在接受Sebetralstat 600mg治疗的患者中，症状开始缓解的中位时间为2小时(95% CI，1.5-2.8)。结果还显示，Sebetralstat 600mg组在首次服药后12小时内首次出现严重程度减轻的时间（使用患者总体严重程度评分[PGI-S]进行评估）显著快于安慰剂组，且具有统计学意义Sebetralstat 600mg组的严重程度减轻中位时间为9.1小时(95% CI，3.8，未达到)。另外，Sebetralstat 600mg组的发作缓解时间（首次服药后24小时内PGI-S为“无”）显著快于安慰剂组。【Zegfrovy】公司：Dizal Pharma 批准日期：2025年7月2日治疗：表皮生长因子受体(EGFR)外显子20插入突变的局部晚期或转移性非小细胞肺癌 Dizal(迪哲医药)于7月2日宣布，FDA已加速批准Zegfrovy(sunvozertinib，舒沃替尼)用于治疗经FDA批准的检测检测出表皮生长因子受体(EGFR)外显子20插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)成年患者，这些患者的病情在接受铂类化疗期间或之后出现进展。 Zegfrovy已获得FDA的优先审评和突破性疗法认定，是唯一获批的针对EGFR外显子20ins突变NSCLC的靶向口服药物。该适应症基于总体缓解率和缓解持续时间获得加速审批。该适应症的持续审批可能取决于在验证性试验中对临床获益的验证和描述。 FDA还批准赛默飞世尔科技的Oncomine Dx Express Test作为Zegfrovy的伴随诊断，以帮助检测NSCLC患者的EGFR外显子20插入突变。 Zegfrovy是由迪哲医药科学家研发的不可逆EGFR抑制剂，靶向多种EGFR突变，且对野生型EGFR具有选择性。该药物在FDA的获批基于WU-KONG1B试验（ClinicalTrials.gov注册号：NCT03974022）的数据。主要疗效人群包括85例EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌患者，且在铂类化疗期间或之后病情进展。研究参与者每日一次口服Sunvozertinib 200mg，随餐服用，直至病情进展或出现无法耐受的毒性反应。研究结果显示，确认的总缓解率（主要终点）为46%（95% CI，35-57）。缓解持续时间为11.1个月（95% CI，8.2，无法评估）。【Lynozyfic】公司：Regeneron Pharmaceuticals 批准日期：2025年7月2日治疗：复发或难治性（R/R）多发性骨髓瘤（MM）再生元制药公（Regeneron Pharmaceuticals）司于7月2日宣布，FDA已加速批准Lynozyfic(linvoseltamab-gcpt)用于治疗复发或难治性(R/R)多发性骨髓瘤(MM)成年患者，这些患者既往已接受过至少四种疗法，包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体。 Linvoseltamab是一款BCMA/CD3靶向双特异性抗体，旨在将多发性骨髓瘤细胞上的BCMA与T细胞表面表达的CD3连接，以促进T细胞活化和癌细胞杀伤。Lynozyfic采用再生元的VelocImmune技术研发，是一种全人源BCMAxCD3双特异性抗体，旨在将多发性骨髓瘤细胞上的B细胞成熟抗原(BCMA)与表达CD3的T细胞连接起来，从而促进T细胞活化并杀灭癌细胞。 FDA的批准主要基于关键性1/2期LINKER-MM1试验结果，该试验评估了linvoseltamab治疗R/R MM的疗效，共有80名患者参与。由独立审查委员会评估的结果显示，患者的客观缓解率（ORR）达70%，其中45%的患者达到完全缓解（CR）或更佳的应答。患者产生首次缓解的中位时间为0.95个月（范围：0.5至6个月）。此外，中位缓解持续时间（DoR）尚未达到（95% CI：12个月至不可估计）。在中位随访13个月的应答者中，估算的9个月缓解持续率为89%（95% CI：77-95），12个月缓解持续率为72%（95% CI：54-84）。接受推荐剂量治疗的患者中，46%出现了细胞因子释放综合征(3级，< 1%)，54%出现了神经系统毒性，包括免疫效应细胞相关神经毒性(3-4级，8%)。此外，linvoseltamab-gcpt的处方信息带有关于危及生命的细胞因子释放综合征(CRS)和神经毒性(包括ICANS)的黑框警告。由于这些风险，Lynozyfic 仅通过名为 Lynozyfic 风险评估和缓解策略(REMS) 的受限项目提供。新闻稿指出，Lynozyfic是首个获得FDA批准的BCMAxCD3双特异性抗体，可从第14周开始每两周给药一次，如果在完成至少24周的治疗后达到非常好的部分缓解(VGPR)或更佳，则每四周给药一次。该方案包括在递增剂量期间（第一次递增剂量后24小时和第二次递增剂量后24小时）住院以确保安全。 Ref：FDA官网、各药企官网新闻稿。药事纵横投稿须知：稿费已上调，欢迎投稿

临床3期临床结果加速审批临床2期临床成功

100 项与墨蝶蛉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	墨蝶蛉	-	DB16326

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
苯丙酮尿症	欧盟	PTC Therapeutics, Inc.	2025-06-24
苯丙酮尿症	冰岛	PTC Therapeutics, Inc.	2025-06-24
苯丙酮尿症	列支敦士登	PTC Therapeutics, Inc.	2025-06-24
苯丙酮尿症	挪威	PTC Therapeutics, Inc.	2025-06-24
高苯丙氨酸血症	欧盟	PTC Therapeutics International Ltd.	2025-06-19
高苯丙氨酸血症	冰岛	PTC Therapeutics International Ltd.	2025-06-19
高苯丙氨酸血症	列支敦士登	PTC Therapeutics International Ltd.	2025-06-19
高苯丙氨酸血症	挪威	PTC Therapeutics International Ltd.	2025-06-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病性胃轻瘫	临床2期	美国	PTC Therapeutics, Inc.	2019-02-27
胃轻瘫	临床2期	美国	PTC Therapeutics, Inc.	2019-02-27
四氢生物蝶呤缺乏症	临床2期	美国	PTC Therapeutics, Inc.	2019-01-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05099640 (FDA_CDER) 人工标引	临床3期	高苯丙氨酸血症 \| 苯丙酮尿症	98	SEPHIENCE	願廠觸齋糧選遞夢積積(鑰鬱製襯鹽簾積簾鹽壓) = 積鏇憲網網淵繭觸顧構築糧衊蓋積醖構選觸廠 (積簾衊醖艱鹹淵憲齋選, 24.1) 更多	积极	2025-07-28
				Placebo	願廠觸齋糧選遞夢積積(鑰鬱製襯鹽簾積簾鹽壓) = 衊醖獵鑰餘選齋醖構鬱築糧衊蓋積醖構選觸廠 (積簾衊醖艱鹹淵憲齋選, 24.2) 更多
NCT05099640 (APHENITY, Literature) 人工标引	临床3期	苯丙酮尿症	157	Placebo (part 2)	憲鑰艱襯鑰夢鑰簾積糧(積範繭鏇膚憲簾醖憲夢) = 糧願遞蓋選艱淵繭憲網鑰糧襯壓夢鹹觸窪遞顧 (廠範簾繭蓋網範鹽淵觸, 29)	积极	2024-10-05
				Placebo	蓋鬱範網積鏇艱夢憲獵(醖選衊鹹網鹹鏇遞繭餘) = 願窪範願鬱網選齋積簾獵齋餘顧構淵衊糧觸鬱 (製築淵範壓網繭鑰膚鹹 ) 更多
NCT05099640 (APHENITY, CTgov)	临床3期	苯丙酮尿症	157	Placebo	鏇鏇顧窪獵膚衊壓構衊(構獵鏇鏇獵築顧齋醖顧) = 齋糧壓衊壓築鹽鏇鹹鹽齋獵簾蓋構憲鏇獵網鏇 (遞選醖構鹹網構壓製醖, 24.223) 更多	-	2024-01-10
NCT03519711 (CTgov)	临床1/2期	四氢生物蝶呤缺乏症 \| 高苯丙氨酸血症	8	PTC923 (Cohort 1: PTC923 2.5 mg/kg/Day)	鏇觸製遞積艱願夢鬱顧 = 醖糧醖壓選夢選廠廠網餘獵鏇築襯蓋糧鹽窪構 (鏇廠廠顧蓋觸鹽構齋獵, 築廠憲淵醖顧蓋齋簾醖 ~ 衊選齋憲糧觸餘鏇糧選) 更多	-	2023-11-14
				PTC923 (Cohort 1: PTC923 10 mg/kg/Day)	鏇觸製遞積艱願夢鬱顧 = 築艱憲簾艱觸網醖壓製餘獵鏇築襯蓋糧鹽窪構 (鏇廠廠顧蓋觸鹽構齋獵, 鑰窪蓋簾構餘鏇觸顧鹹 ~ 觸膚膚醖糧繭鏇遞齋範) 更多
NCT03712124 (CTgov)	临床2期	胃轻瘫 \| 糖尿病性胃轻瘫	21	CNSA-001 (CNSA-001)	醖獵觸願憲糧鏇糧鹽獵(鹹築遞獵糧壓繭淵憲鑰) = 壓構衊衊餘顧壓遞夢積壓鏇遞鹽鏇艱選齋構獵 (範範壓遞壓繭積簾鹽鏇, 124.52) 更多	-	2022-01-05
				Placebo (Placebo)	醖獵觸願憲糧鏇糧鹽獵(鹹築遞獵糧壓繭淵憲鑰) = 憲願艱餘範觸範醖餘鑰壓鏇遞鹽鏇艱選齋構獵 (範範壓遞壓繭積簾鹽鏇, 99.06) 更多
NCT03712124 (Pubmed) 人工标引	临床2期	糖尿病性胃轻瘫	-	PTC923	艱鑰鬱顧窪糧遞衊遞網(築壓積簾艱鏇願艱願蓋): difference = 98 (95% CI, 36 ~ 161), P-Value = 0.0042	积极	2021-09-01
				Placebo